Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-07-19
2011-12-20
Kelly, Robert M (Department: 1633)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S094100, C435S069700
Reexamination Certificate
active
08080637
ABSTRACT:
The invention provides a method to treat a complication of neuronal injury in a mammal by inhibiting the complement cascade.
REFERENCES:
patent: 6140472 (2000-10-01), Rosengard et al.
patent: 6184248 (2001-02-01), Lee et al.
patent: WO 9944625 (1999-09-01), None
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Verma, et al. (1997) Nature, 389: 239-42.
Kotwal, et al. (2002) Ann. NY. Acad. Sci., 973: 317-322.
Statler, et al. (2001) J. Neurotrauma, 18(11): 1195-206.
Langer (2003) Sci. Am., 288(4): 51-57.
Rudinger (1976) Peptide Hormones, Univ. Park Press, Baltimore, MD, pp. 1-7.
Bowie, et al. (1990) Science, 247: 1306-10.
Stelmasiak, et al. (2000) Med. Sci. Monit., 6(2): 426-32.
The Merck Manual, 17th Edition, Merck Research Laboratories, (1999), pp. 1022-1023.
Al-Mohanna, Futwan, et al., “Vaccinia Virus Complement Control Protein is Capable of Protecting Xenoendothelial Cells From Antibody Binding and Killing by Human Complement and Cytotoxic Cells”,Transplantation, vol. 71, No. 6, (Mar. 27, 2001), pp. 796-801.
Bellander, Bo-Michael, et al., “Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat”,J. Neurosurg, vol. 85, (Sep. 1996), pp. 468-475.
Daly, J., et al., “Pro-Inflammatory Complement Activation by the Aβ Peptide of Alzheimer's Disease is Biologically Significant and Can Be Blocked by Vaccinia Virus Complement Control Protein”,Neurobiology of Aging, vol. 19, No. 6, (1998), pp. 619-627.
Frank, M.M., et al., “The role of complement in inflammation and phagocytosis”,Immunology Today, vol. 12, No. 9, (1991), pp. 322-326.
Furlong, S.T., et al., “C3 activation is inhibited by arralogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles”,Immunopharmacology, vol. 48, (2000), pp. 199-212.
Hicks, R., et al., “Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat”,Acta Neuropathol, vol. 91, (1996), pp. 236-246.
Horstick, G., et al., “Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium Dose-Related Beneficial Versus Detrimental Effects”,Circulation, (Dec. 2001), pp. 3125-3131.
Inal, J., et al., “Complement C2 Receptor Inhibitor Trispanning and the β-Chain of C4 Share a Binding Site for Complement C2”,The Journal of Immunology, (2002), pp. 5213-5221.
Isaacs, S.N., et al., “Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence”,Proc. Natl. Acad. Sci. USA, vol. 89, (Jan. 1992), pp. 628-632.
Kaczorowski, S.L., et al., “Effect of Soluble Complement Receptor-1 on Neutrophil Accumulation After Traumatic Brain Injury in Rats”,Journal of Cerebral Blood Flow and Metabolism, vol. 15, No. 5, (1995), pp. 860-864.
Keeling, K.L., et al., “Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system” ,Journal of Neuroimmunology, vol. 105, (2000), pp. 20-30.
Kirschfink, M., “Controlling the complement system in inflammation”,Immunopharmacology, vol. 38, (1997), pp. 51-62.
Kirschfink, M., “Targeting complement in therapy”,Immunological Reviews, vol. 180, (2001), pp. 177-189.
Kotwal, G.J., “Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus”,Science, vol. 250, (Nov. 9, 1990), pp. 827-830.
Kotwal, G.J., “Microorganisms and their interation with the immune system”,Journal of Leukocyte Biology, vol. 62, (Oct. 1997), pp. 415-429.
Kotwal, G.J., et al., “Poxviral mimicry of complement and chemokine system components: what's the end game?”,Immunology Today, vol. 21, No. 5, (May 2000), pp. 242-248.
Kotwal, G.J., et al., “The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation”,Molecular and Cellular Biochemistryvol. 185, (1998), pp. 39-46.
Kotwal, G.J., et al., “Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins”,Nature, vol. 335, (Sep. 8, 1988), pp. 176-178.
Levin, H.S., et al., “Neurobehavioral outcome following minor head injury: a three-center study”,J. Neurosurg., vol. 66, (Feb. 1987), pp. 234-243.
McKenzie, R., et al., “Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein”,The Journal of Infectious Diseases, vol. 166, (1992), pp. 1245-1250.
Monsinjon, T., et al., “Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement”,Fundamental&Clinical Pharmacology, vol. 15, (2001), pp. 293-306.
Morgan, B.P., et al., “Expression of complement in the brain: role in health and disease”,Immunology Today, vol. 17, No. 10, (Oct. 1996), pp. 461-466.
Murthy, Krishna H.M., et al., “Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate Proteoglycans”,Cell, vol. 104, (Jan. 26, 2001), pp. 301-311.
Nagahama, M.,et al., “Adenovirus-mediated gene transfer of triple human complement regulating proteins (DAF, MCP and CD59) in the xenogeneic porcine-to-human transplantation model”,Transpl. Int., vol. 15, (2002), pp. 205-211.
Reynolds, D.N, et al., “Heparin Binding Activity of Vaccinia Virus Protein Confers Additional Properties of Uptake by Mast Cells and Attachment to Endothelial Cells”,Advances in Animal Virology, (Nov. 1998), pp. 337-342.
Roos, A. et al., “Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides”,The Journal of Immunology, (2001), pp. 7052-7059.
Rosengard, A.M., et al., “Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complement”,PNAS, vol. 99, No. 13, (Jun. 25, 2002), pp. 8808-8813.
Smith, S.A., et al., “Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense” ,Journal of Virology, (Jun. 2000), pp. 5659-5666.
Soares, H.D., et al., “Inflammatory Leukocytic Recruitment and Diffuse neuronal Degeneration Are Separate Pathological Processes Resulting from Traumatic Brain Injury”,The Journal of Neuroscience, vol. 15, No. 12, (Dec. 1995), pp. 8223-8233.
Stahel, P.F., et al., “The role of the complement system in traumatic brain injury”,Brain Research Reviews, vol. 27, (1198), pp. 243-256.
Strachan, A.J., et al., “Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of small molecule C5a receptor antagonist”,British Journal of Pharmacology, vol. 134, (2001), pp. 1778-1786.
Tanno, H., et al., “Breakdown of the Blood-Brain Barrier after Fluid Percussive Brain Injury in the Rat. Part 1: Distribution and Time Course of Protein Extravasation”,Journal of Neurotrauma, vol. 9, No. 1, (1992), pp. 21-32.
Smith et al., 1991, “Evaluation of Memory Dysfunction Following Experimental Brain Injury Using the Morris Water Maze”,J. Neurotrauma, 8:259-269.
Gennarelli, 1994, “Animate Models of Human Head Injury”,J. Neurotrauma, 11:357-368.
McIntosh et al., 1989, “Traumatic Brain Injury in the Rat: Characterization of a Lateral Fluid-Percussion Modelȁ
Hicks Ramona
Kotwal Girish J.
Fish & Richardson P.C
Kelly Robert M
Kotwal Bioconsulting, LLC
Parsons Angela
LandOfFree
Therapeutic method of treating brain trauma in rodents with VCP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic method of treating brain trauma in rodents with VCP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic method of treating brain trauma in rodents with VCP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4257920